Guggenheim initiates coverage of Faeth Therapeutics with Buy
Guggenheim initiated coverage of Faeth Therapeutics with a Buy rating and a $70.00 price target.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.